EKSO - Ekso Bionics Holdings, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.9800
+0.0800 (+2.05%)
As of 2:07PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close3.9000
Open3.8700
Bid3.9600 x 1200
Ask4.0000 x 1000
Day's Range3.8201 - 4.0100
52 Week Range2.2500 - 23.5500
Volume69,221
Avg. Volume111,400
Market Cap23.257M
Beta (5Y Monthly)2.05
PE Ratio (TTM)N/A
EPS (TTM)-1.5910
Earnings DateApr 30, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Ekso Bionics Announces CFIUS Determination Regarding China Joint Venture

    Ekso Bionics Holdings, Inc. (EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported that the Company, Zhejiang Youchuang Venture Capital Investment Co., Ltd and another partner (collectively, the “JV Partners”) received notice from the Committee on Foreign Investment in the United States (“CFIUS”) in connection with its review of the Company’s and the JV Partners’ investment in Exoskeleton Intelligent Robotics Co. Limited (the “JV”). The notice states that CFIUS’s prior national security concerns regarding the JV could not be mitigated and, in connection with its determination, CFIUS presented the Company and the JV Partners with a National Security Agreement (“NSA”), which will, among other things, require the termination of the Company’s role with the JV.

  • Analysts Suggest Buying These 2 Falling Knives
    GuruFocus.com

    Analysts Suggest Buying These 2 Falling Knives

    Their share prices are predicted to buonce back strongly Continue reading...

  • Thomson Reuters StreetEvents

    Edited Transcript of EKSO earnings conference call or presentation 30-Apr-20 8:30pm GMT

    Q1 2020 Ekso Bionics Holdings Inc Earnings Call

  • GlobeNewswire

    Ekso Bionics Reports First Quarter 2020 Results

    RICHMOND, Calif., April 30, 2020 -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use,.

  • GlobeNewswire

    Ekso Bionics® to Report First Quarter 2020 Financial Results on April 30, 2020

    Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2020 after the close of trading on Thursday, April 30, 2020. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. Investors interested in listening to the conference call may do so by dialing (877) 407-3036 for domestic callers or (201) 378-4919 for international callers.

  • GlobeNewswire

    Ekso Bionics Provides COVID-19 Business Update and Reports Preliminary First Quarter 2020 Financial Results

    Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary financial results for the first quarter ended March 31, 2020 and provided an update on the impact of the COVID-19 pandemic on its business activities. In addition, the Company confirmed that as of April 7, 2020, it has regained compliance with the minimum bid price requirement required by the listing rules of the Nasdaq Capital Market. The COVID-19 pandemic impacted Ekso Bionics' business in the first quarter as its customers shifted their priorities to prepare for and manage their business during the pandemic.

  • GlobeNewswire

    Ekso Bionics® Announces Reverse Stock Split

    Ekso Bionics Holdings, Inc. (the “Company”) (EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of March 24, 2020 at 1:05 p.m. Pacific time. The Company’s common stock will open for trading on The Nasdaq Capital Market on March 25, 2020 on a split-adjusted basis under the existing trading symbol “EKSO”. The Company’s common stock will trade under a new CUSIP number 282644301 upon the effectiveness of the reverse stock split.

  • Thomson Reuters StreetEvents

    Edited Transcript of EKSO earnings conference call or presentation 27-Feb-20 9:30pm GMT

    Q4 2019 Ekso Bionics Holdings Inc Earnings Call

  • US$1.43: That's What Analysts Think Ekso Bionics Holdings, Inc. Is Worth After Its Latest Results
    Simply Wall St.

    US$1.43: That's What Analysts Think Ekso Bionics Holdings, Inc. Is Worth After Its Latest Results

    There's been a major selloff in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) shares in the week since it released its...

  • GlobeNewswire

    Ekso Bionics Reports Fourth Quarter and Year End 2019 Results

    RICHMOND, Calif., Feb. 27, 2020 -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use,.

  • GlobeNewswire

    Ekso Bionics® Announces Collaboration with Kindred Healthcare to Pilot EksoNR in Long-Term Acute Care Hospitals

    Ekso Bionics Holdings, Inc. (EKSO), a leading developer of exoskeletons for medical and industrial use, today announced a collaboration with Kindred Healthcare, LLC ("Kindred") to pilot EksoNR— the most clinically used robotic exoskeleton, in their long-term acute care hospitals. Kindred already offers exoskeleton-assisted rehabilitation with the device in over 20 of its freestanding inpatient Kindred rehabilitation hospitals. Kindred is the first network to explore the benefits of EksoNR in the long-term acute care setting.

  • GlobeNewswire

    Ekso Bionics® to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020

    Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2019 after the close of trading on Thursday, February 27, 2020. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. Investors interested in listening to the conference call may do so by dialing (877) 407-3036 for domestic callers or (201) 378-4919 for international callers.

  • GlobeNewswire

    Post Acute Medical (PAM) Accelerates Adoption of Exoskeleton Rehabilitation with Three Additional EksoNR Devices from Ekso Bionics®

    Post Acute Medical, LLC, (PAM), a system of inpatient rehabilitation hospitals, has acquired three additional EksoNR devices from Ekso Bionics (EKSO) to expand the availability of exoskeleton-assisted rehabilitation to seven of its facilities. Exoskeleton-assisted rehabilitation is now available at five PAM locations in Texas. The device is designed to help patients stand and walk during rehabilitation after a stroke or spinal cord injury.

  • Some Ekso Bionics Holdings (NASDAQ:EKSO) Shareholders Have Copped A 96% Share Price Wipe Out
    Simply Wall St.

    Some Ekso Bionics Holdings (NASDAQ:EKSO) Shareholders Have Copped A 96% Share Price Wipe Out

    Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...

  • GlobeNewswire

    Ekso Bionics® Releases its Upgraded EksoPulse Platform, Advanced Cloud-Based Analytics for Robotic Exoskeleton-Assisted Rehabilitation

    Ekso Bionics Holdings, Inc. (EKSO), a leading developer of robotic exoskeletons, today announced the worldwide launch of its upgraded EksoPulse platform, an innovative cloud-based information technology platform that measures and analyzes progress using the EksoNR robotic exoskeleton. The improved analytics system provides an easy-to-use dashboard to chart activity in rehabilitation sessions, enhancing the clinician, institutional, and patient experience of the most clinically used exoskeleton. The new EksoPulse platform technology uniquely allows physical therapists and physicians to track and personalize patient care with EksoNR.

  • GlobeNewswire

    Ekso Bionics Reports Preliminary Fourth Quarter and Full Year 2019 Financial Results; Company Achieves Record Fourth Quarter Revenue

    Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the fourth quarter and fiscal year ended December 31, 2019. Total revenue for the fourth quarter of 2019 is an estimated $3.7 million, reflecting year-over-year growth of 12.1% compared to total revenue of $3.3 million in the fourth quarter of 2018, and the highest quarterly revenue ever recorded by the Company. Estimated total revenue for the fourth quarter of 2019 includes approximately $3.2 million in medical revenue.

  • Should You Buy Ekso Bionics Holdings, Inc. (EKSO)?
    Insider Monkey

    Should You Buy Ekso Bionics Holdings, Inc. (EKSO)?

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

  • GlobeNewswire

    Ekso Bionics Announces Closing of $5.0 Million Registered Direct Offering

    Ekso Bionics Holdings, Inc. (EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the closing of its previously announced registered direct offering of 11,111,116 shares of its common stock and warrants to purchase up to 8,333,337 shares of its common stock, at a combined purchase price of $0.45 per share and associated warrant, for aggregate gross proceeds of approximately $5.0 million. The Company currently intends to use the net proceeds from the offering for general corporate purposes and working capital needs. The securities described above were offered and sold by the Company pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-218517), including a base prospectus, previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”) on June 16, 2017.

  • GlobeNewswire

    Ekso Bionics® Expands Distribution of the EksoVest to Northern Europe

    Ekso Bionics Holdings, Inc. (EKSO), a leading developer of exoskeletons for medical and industrial use, today announced it signed a distribution agreement with the largest Danish-owned distributor of building materials, BYGMA GRUPPEN A/S, to make the EksoVest available in Northern Europe. The Bygma Group is a solid Nordic group ranking among the top 100 companies in Denmark.

  • GlobeNewswire

    Ekso Bionics Announces $5.0 Million Registered Direct Offering

    Ekso Bionics Holdings, Inc. (EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of 11,111,116 shares of its common stock and warrants to purchase up to 8,333,337 shares of its common stock, at a combined purchase price of $0.45 per share and associated warrant, for aggregate gross proceeds of approximately $5.0 million. The Company currently intends to use the net proceeds from the offering for general corporate purposes and working capital needs. The securities described above are being offered and sold by the Company pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-218517), including a base prospectus, previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”) on June 16, 2017.

  • Health Check: How Prudently Does Ekso Bionics Holdings (NASDAQ:EKSO) Use Debt?
    Simply Wall St.

    Health Check: How Prudently Does Ekso Bionics Holdings (NASDAQ:EKSO) Use Debt?

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • Thomson Reuters StreetEvents

    Edited Transcript of EKSO earnings conference call or presentation 30-Oct-19 8:30pm GMT

    Q3 2019 Ekso Bionics Holdings Inc Earnings Call

  • GlobeNewswire

    Ekso Bionics Reports Third Quarter 2019 Results

    RICHMOND, Calif., Oct. 30, 2019 -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use,.

  • GlobeNewswire

    Ekso Bionics® to Report Third Quarter 2019 Financial Results on October 30, 2019

    Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2019 after the close of trading on Wednesday, October 30, 2019. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. Investors interested in listening to the conference call may do so by dialing (877) 407-3036 for domestic callers or (201) 378-4919 for international callers.

  • Selling Tools to Miners: The Stocks That Can Profit on Biotech and Prosthetics
    GuruFocus.com

    Selling Tools to Miners: The Stocks That Can Profit on Biotech and Prosthetics

    Determining which medical technology companies can increase their stock price Continue reading...